CRBU CARIBOU BIOSCIENCES INC

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT.

For more information and a link to the , visit the page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow us @CaribouBio and visit .

Caribou Biosciences, Inc. contacts:

Investors:

Amy Figueroa, CFA

Media:

Peggy Vorwald, PhD



EN
06/05/2025

Underlying

CRBUCARIBOU BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CARIBOU BIOSCIENCES INC

 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences to Participate in the Jefferies Global Healthcare ...

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT. For more information and a link to the , visit the page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event. About ...

May 28, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences Reports First Quarter 2025 Financial Results and P...

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update -- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 -- BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2025 and provided a business update for it...

May 8, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences to Participate in the BofA Securities 2025 Health ...

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT. For more information and a link to the , visit the page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the even...

May 6, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences Announces Strategic Pipeline Prioritization with F...

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs -- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 -- -- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 CaMMouflage r/r MM Phase 1 dose escal...

April 24, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financia...

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update -- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- -- $249.4 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2026 -- BERKELEY, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharm...

March 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch